Prevention of hepatitis A by Havrix™: A review

Expert Review of Vaccines

Volumn 4, Issue 4, 2005, Pages 459-471

  Van Herck, Koen ^a   Van Damme, Pierre ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Havrix ; Hepatitis A vaccine; Long term protection; Outbreak control; Safety; Universal mass vaccination; Vaccine efficacy; Vaccine immunogenicity; Vaccine reactogenicity

Indexed keywords

HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATYRIX; ILLICIT DRUG; IMMUNOGLOBULIN G; TYPHOID VACCINE;

ANTIBODY TITER; BLOOD CLOTTING FACTOR DEFICIENCY; CLINICAL TRIAL; DAY CARE; ENDEMIC DISEASE; EPIDEMIC; FOLLOW UP; FOOD HANDLING; HEALTH CARE PERSONNEL; HEPATITIS A; HEPATITIS A VIRUS; HIGH RISK POPULATION; HOMOSEXUALITY; HUMAN; HUMORAL IMMUNITY; HYGIENE; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INTRAVENOUS DRUG ABUSE; MASS IMMUNIZATION; MATHEMATICAL MODEL; MORTALITY; OCCUPATIONAL DISEASE; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; SEROPREVALENCE; T LYMPHOCYTE; TRAVEL; VACCINATION;

ANIMALS; HEPATITIS A; HEPATITIS A VACCINES; HEPATITIS A VIRUS, HUMAN; HUMANS; VACCINES, INACTIVATED;

EID: 24744462538     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.4.4.459     Document Type: Review

References (144)

1. World Health Organization. Hepatitis A vaccines WHO position paper. Wkly Epidemiol. Rec. 75, 38-44 (2000).
2. Allen CJ, Person MJ. Notification of infectious diseases by general practitioners: a quantitative and qualitative study. Med. J. Aust. 172, 325-328 (2000).
3. Roels TH, Christl M, Kazmierczak JJ et al. Hepatitis A infections in Wisconsin: trends in incidence and factors affecting surveillance, 1986-1995. WMJ 97, 32-38 (1998).
4. Hadler SC. Global impact of hepatitis A virus infection; changing patterns. In: Viral Hepatitis and Liver Diseases. Hollinger FB, Lemon SM, Margolis HS (Eds). Williams & Wilkins, Baltimore, MD, USA, 14-20 (1991).
5. Koff RS. Hepatitis A. Lancet 351, 1643-1648 (1998).
6. Berge JJ, Drennan DP, Jacobs RJ et al. The cost of hepatitis A infections in American adolescents and adults in 1997. Hepatology 31, 469-473 (2000).
7. Van Damme P, Bell B. Meeting report. Hepatitis A: how to match prevention strategies to changing epidemiology. Vaccine 19, 999-1002 (2001).
8. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 48(RR-12) 1-37 (1999).
9. Centers for Disease Control and Prevention. Hepatitis Surveillance Report No. 57. Centers for Disease Control and Prevention, Atlanta, GA, USA (2000).
10. Bell BP, Shapiro CN, Alter MJ et al. The diverse patterns of hepatitis A epidemiology in the United States - implications for vaccination strategies. J. Infect. Dis. 178, 1579-1584 (1998).
11. O'Grady JG. Fulminant hepatitis in patients with chronic liver disease. J. Viral. Hepat. 7(Suppl. 1), 9-10 (2000).
12. Debray D, Cullufi P, Devictor D, Fabre M, Bernard O. Liver failure in children with hepatitis A. Hepatology 26, 1018-1022 (1997).
13. Ciocca M. Clinical course and consequences of hepatitis A infection. Vaccine 18, S71-S74 (2000).
14. Lednar WM, Lemon SM, Kirkpatrick JW, Redfield RR, Fields ML, Kelley PW. Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am. J. Epidemiol. 122, 226-33 (1985).
15. Hadler SC, Webster HM, Erben JJ, Swanson JE, Maynard JE. Hepatitis A in daycare centers: a community-wide assessment. N. Engl. J. Med. 302, 1222-1227 (1980).
16. Smith S, Weber S, Wiblin T, Nettleman M. Cost-effectiveness of hepatitis A vaccination in healthcare workers. Infect. Control Hosp. Epidemiol. 18, 688-691 (1997).
17. Banatvala J. Epidemiology of hepatitis A (HAV) in Europe and its relationship to immunisation. In: Proceedings of the International Symposium on enterically-transmitted hepatitis viruses. Buisson Y, Coursaget P, Kane M (Eds). La Simarre, Tours, France, 72-77 (1996).
18. Jacobsen KH, Koopman JS. Declining hepatitis A seroprevalence: a global review and analysis. Epidemiol. Infect. 132(6), 1005-1022 (2004).
19. Barzaga NG. Hepatitis A shifting epidemiology in South-East Asia and China. Vaccine 18, S61-S64 (2000).
20. Poovorawan Y, Chatchatee P, Chongsrisawat V. Epidemiology and prophylaxis of viral hepatitis: a global perspective. J. Gastroenterol. Hepatol 17(Suppl.) S155-S166 (2002).
21. Chatchatee P, Chongsrisawat V, Theamboonlers A, Poovorawan Y. Declining hepatitis A seroprevalence among medical students in Bangkok, Thailand, 1981-2001. Asian Pac. J. Allergy Immunol. 20(1), 53-56 (2002).
22. Joussemet M, Depaquit J, Nicand E et al. Fall in the seroprevalence of hepatitis A in French youth. Gastroenterol. Clin. Biol. 23(4), 447-451 (1999).
23. Frösner GG, Papaevangelou G, Butler R et al. Antibody against hepatitis A in seven European countries. I. Comparison of prevalence data in different age groups. Am. J. Epidemiol. 110, 63-69 (1979).
24. Tilzey A, Banatvala JE. Hepatitis A: changing prevalence and possible vaccines. Br. Med. J. 302, 1551-1552 (1991).
25. Rooney CF, Rodrigues L. Hepatitis A immunization. Br. Med. J. 303, 414 (1991).
26. Loscher T, Keystone JS, Steffen R. Vaccination of travellers against hepatitis A and B. J. Travel Med. 6(2), 107-114 (1999).
27. Barros H, Oliveira F, Miranda H. A survey on hepatitis A in Portuguese children and adolescents. J. Viral. Hepat. 6, 249-253 (1999).
28. Stroffolini T, D'Amelio R, Matricardi PM et al. The changing epidemiology of hepatitis A in Italy. Ital. J. Gastroenterol. 25, 372-374 (1993).
29. Zanetti AR, Romano L, Tanzi E et al. Decline in antiHAV prevalence in the Milan area between 1958 and 1992. Eur. J. Epidemiol. 25, 633-635 (1994).
30. Beutels M, Van Damme P, Vranckx R, Meheus A. The shift in prevalence of hepatitis A immunity in Flanders, Belgium. Acta Gastroenterol. Belg. 61, 4-7 (1998).
31. Polz-Dacewicz MA, Polickiewicz P, Badach Z. Changing epidemiology of hepatitis A virus infection - a comparative study in central eastern Poland. Med. Sci. Monit. 6, 989-993 (2000).
32. Beran J, Douda P, Rychly R. Seroprevalence of viral hepatitis A in the Czech Republic. Eur. J. Epidemiol. 15, 805-808 (1999).
33. Das K, Jain A, Gupta S et al. The changing epidemiological pattern of hepatitis A in an urban population of India: emergence of a trend similar to the European countries. Eur. J. Epidemiol. 16, 507-510 (2000).
34. Yap I, Guan R. Hepatitis A seroepidemiology in Singapore: a changing pattern. Trans. R. Soc. Trop. Med. Hyg. 87, 22-23 (1993).
35. Kalayanarooj S, Vaughn DW, Snitbhan R, Ariyasriwatana C. Age-specific prevalence of hepatitis A antibody in Thai children. Southeast Asian J. Trop. Med. Public Health 26, 709-711 (1995).
36. Poovorawan Y, Vimolkej T, Chongsrisawat V, Theamboonlers A, Chumdermpadetsuk S. The declining pattern of seroepidemiology of hepatitis A virus infection among adolescents in Bangkok, Thailand. Southeast Asian J. Trop. Med. Public Health 28, 154-157 (1997).
37. Sohn YM, Rho HO, Park MS et al. The changing epidemiology of hepatitis A in children and the consideration of active immunization in Korea. Yonsei Med. J. 41, 34-39 (2000).
38. Van Herck K, Zuckerman J, Castelli F, Van Damme P, Walker E, Steffen R. Travellers' knowledge, attitudes, and practices on prevention of infectious diseases: Results from a pilot study. J. Travel Med. 10, 75-78 (2003).
39. Van Herck K, Castelli F, Zuckerman J et al. Knowledge, attitudes and practices regarding travel-related infectious diseases: methodology and results from an airport survey in Europe. J. Travel Med. 11, 3-8 (2004).
40. Toovey S, Jamieson A, Holloway M. Travellers' knowledge, attitudes and practices on the prevention of infectious diseases: Results from a study at Johannesburg International Airport. J. Travel Med. 11, 16-22 (2004).
41. Wilder-Smith A, Khairullah NS, Song JH, Chen CY, Torresi J. Travel health knowledge, attitudes and practices among Australasian travellers. J. Travel Med. 11, 9-15 (2004).
42. Hutin YJ, Pool V, Cramer EH, Nainan OV, Weth J, Williams IT. A multistate, foodborne outbreak of hepatitis A. N. Engl. J. Med. 340, 595-602 (1999).
43. Nalin DR, Kuter BJ, Brown L et al. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. J. Hepatol. 18(Suppl. 2), S51-S55 (1993).
44. Loutan L, Bovier P, Althaus B, Gluck R. Inactivated virosome hepatitis A vaccine. Lancet 343, 322-334 (1994).
45. Vidor E, Fritzell B and Plotkin S. Clinical development of a new inactivated hepatitis A vaccine. Infection 24, 447-458 (1996).
46. Dagan R, Greenberg D, Goldenbertg-Gehtman P et al. Safety and immunogenicity of a new formulation of an inactivated hepatitis A vaccine. Vaccine 17, 1919-1925 (1999).
47. Van Damme P, Van Herck K. Effect of hepatitis A vaccination programs. JAMA 294(2), 246-248 (2005)
48. Innis BL, Snitbhan R, Kunasol P et al. Protection against hepatitis A by an inactivated vaccine. JAMA 271, 1328-1334 (1994).
49. Werzberger A, Mensch B, Kuter B et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N. Engl. J. Med. 327(7), 453-457 (1991).
50. Ambrosch F, Wiedermann G, Jonas S et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 15(11), 1209-1213 (1997).
51. Zamir C, Rishpon S, Zamir D, Leventhal A, Rimon N, Ben-Porath E. Control of a community-wide outbreak of hepatitis A by mass vaccination with inactivated hepatitis A vaccine. Eur. J. Clin. Microbiol. Infect. Dis. 20, 185-187 (2001).
52. Stapleton JT, Lemon SM. New vaccines against hepatitis. In: New Generation Vaccines. Levine MM, Woodrow GC, Kaper JB, Cobon GS (Eds), Marcel Dekker, Inc., New York, NY, USA 571-585 (1997).
53. André F, Van Damme P, Safary A, Banatvala J. Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. Expert Rev. Vaccines 1(1), 9-23 (2002).
54. Van Damme P, Banatvala J, Fay O et al. Consensus Statement: Hepatitis A booster vaccination: is there a need? Lancet 362, 1065-1071 (2003).
55. Miller MJ. Summary of current nomenclature, taxonomy and classification of various microbial agents. Clin. Infect. Dis. 16, 597-615 (1993).
56. Peetermans J. Production quality control and characterization of an inactivated hepatitis A vaccine. Vaccine 10(1), S99-S101 (1992).
57. André FE, D'Hondt E, Delem A, Safary A. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: Rationale and summary of findings. Vaccine 10(1), S160-S169 (1992).
58. Hollinger FB, André FE, Melnick J, (Eds). Proceedings of International Symposium on active immunization against hepatitis A. Vaccine 1, S1-S176 (1992).
59. Connor BA, Van Herck K, Van Damme P. Rapid protection and vaccination against Hepatitis A for travellers. Biodrugs 17(Suppl. 1), 19-21 (2003).
60. Bryan JP, Henry CH, Hoffman AG et al. Randomized, cross-over, controlled comparison of two inactivated hepatitis A vaccines. Vaccine 19, 743-750 (2001).
61. Clemens R, Safary A, Hepburn A, Roche C, Stanbury W, Andre F. Clinical experience with an inactivated hepatitis A vaccine. J. Infect. Dis. 171(Suppl. 1), S44-S49 (1995).
62. Braconier JH, Wennerholm S, Norrby SR. Comparative immunogenicity and tolerance of Vaqta™ and Havrix™. Vaccine 17, 2181-2184 (1999).
63. Ashur Y, Adler R, Rowe M, Shouval D. Comparison of immunogenicity of two hepatitis A vaccines - VAQTA and HAVRIX® - in young adults. Vaccine 17, 2290-2296 (1999).
64. Holzer BR, Hatz C, Smith T, Sissolak D, Gluck R, Egger M. Immunogenicity and risk effects of IRIV versus A1(OH3) hepatitis A vaccine: a randomised controlled trial. Schweiz. Med. Wochenschr. 125(Suppl. 63), 109 (1994).
65. Holzer BR, Hatz C, Schmidt-Sissolak D, Gluck R, Althams B, Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-absorbed hepatitis A vaccine: a randomised controlled trial. Vaccine 14(10), 982-986 (1996).
66. Ambrosch F, Finkel B, Herzog C, Koren A, Kollaritsch H. Rapid antibody response after vaccination with a virosomal hepatitis A vaccine. Infection 32, 149-152 (2004).
67. Usonis V, Bakasénas V, Valentelis R, Katiliene G, Vidzeniene D, Herzog C. Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal®). Vaccine 21, 4588-4592 (2003).
68. Landry P, Tremblay S, Darioli R et al. Inactivated hepatitis A vaccine booster given ≥24 months after the primary dose. Vaccine 19, 399-402 (2001).
69. Iwarson S, Lindh M, Widerstrom L. Excellent booster response 4-6 y after a single primary dose of an inactivated hepatitis A vaccine. Scand. J. Infect. Dis. 34(2), 110-111 (2002).
70. Iwarson S, Lindh M, Widerstrom L. Excellent booster response 4 to 8 years after a single primary dose of an inactivated hepatitis A vaccine. J. Travel Med. 11, 120-121 (2004).
71. Williams JL, Bruden DA, Cagle HH et al. Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults. Vaccine 21, 3208-3211 (2003).
72. Beck BR, Hatz C, Bronnimann R, Herzog C. Successful booster antibody response up to 54 months after single primary vaccination with virosome- formulated, aluminum-free hepatitis A vaccine. Clin. Infect. Dis. 37(9), e126-e128. (2003).
73. Gil A, Gonzalez A, Dal-Re R, Calero JR. Interference assessment of yellow fever vaccine with the immune response to a single dose of inactivated hepatitis A vaccine (1440 El.U). A controlled study in adults. Vaccine 14, 1028-1030 (1996).
74. Van Hoecke C, Lebacq E, Beran J, Prymula R, Collard F. Concomitant vaccination against hepatitis A and typhoid fever. J. Travel Med. 5, 116-120 (1998).
75. Bock HL, Kruppenbacher JP, Bienzle U, De Clercq NA, Hoffmann F, Clemens RL. Does the concurrent administration of an inactivated hepatitis A vaccine influence the immune response to other travellers vaccines? J. Travel Med. 7, 74-78 (2000).
76. Thoelen S, Van Damme P, Leentvaar-Kuijpers A et al. The first combined vaccine against hepatitis A and B: an overview. Vaccine 17, 1657-1662 (1999).
77. Joines RW, Blatter M, Abraham B et al. A prospective, randomised, comparative US trial of a combination hepatitis A and B vaccine (Twinrix®) with corresponding monovalent vaccines (Havrix® and Engerix-B®) in adults. Vaccine 19, 4710-4719 (2001).
78. Tsai I-J, Chang M-W, Chen H-L et al. Immunogenicity and reactogenicity of the combined hepatitis A and B vaccine in young adults. Vaccine 19(4-5), 437-441 (2001).
79. Beran J, Beutels M, Levie K et al. A single dose, combined vaccine against typhoid fever and hepatitis A: consistency, immunogenicity and reactogenicity. J. Travel Med. 7(5), 246-52 (2000).
80. Burke DS and Nimmanniya S. Passively acquired antibody to hepatitis A virus in Thai infants. Southeast Asian J. Trop. Med. Public Health 11, 415-6 (1980).
81. Vargas V, Pedreira JD, Esteban R, Hernandez JM, Guardia J, Bacardi R. Materno-fetal transmission of hepatitis A antibody. Acta Paediatr. Scand. 69, 533 (1980).
82. Troisi CL, Hollinger FB, Krause DS, Pickering LK. Immunization of seronegative infants with hepatitis A vaccine (Havrix™, SKB): a comparative study of two dosing schedules. Vaccine 15, 1613-1617 (1997).
83. Piazza M, Safary A, Vegnente A. Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in die childhood vaccination programme. Vaccine 17, 585-588 (1999).
84. Kanra G, Yalcin SS, Ceyhan M, Yurdakok K. Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children. Turk. J. Pediatr. 42, 105-108 (2000).
85. Dagan R, Amir J, Mijalovsky A et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr. Infect. Dis. J. 19, 1045-1052 (2000).
86. Letson GW, Craig NS, Kuehn D et al. Effect of maternal antibody on immunogenicity of hepatitis a vaccine in infants. J. Pediatr. 144, 327-332 (2004).
87. Briem H, Safary A. Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later. J. Med. Virol. 44, 443-445 (1994).
88. Paganelli R, Scala E, Quinti I, Ansotegui IJ. Humoral immunity in aging. Aging (Milano) 6, 143-150 (1994).
89. Stoffel M, Lievens M, Dieussaert I, Martin I, Andre F. Immunogenicity of Twinrix in older adults: a critical analysis. Expert Rev. Vaccines 2, 9-14 (2003).
90. Nothdurft HD. Letter to the editor. Vaccine 22, 592-593 (2004).
91. Wolters B, Junge U, Dziuba S, Roggendorf M. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine 21, 3623-3628 (2003).
92. Van Damme P, Van Herck K, Van der Wielen M. Combined hepatitis A and B vaccine in elderly. Vaccine 22, 303-304 (2004).
93. Riedemann S, Reinhardt G, Frosner GG et al. Placebo-controlled efficacy study of hepatitis A vaccine in Valdivia, Chile. Vaccine 10(Suppl. 1), S152-S155 (1992).
94. Van Herck K, Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J. Med. Virol. 63(1), 1-7 (2001).
95. Werzberger A, Kuter B, Nalin D. Six years' follow-up after hepatitis A vaccination. N. Engl. J. Med. 338, 1160 (1998).
96. Proceedings of the 11th International Symposium on Viral Hepatitis and Liver Disease, Sydney, 2003. Jilbert AR, Grgacic EVL, Vickery K, Cossart YE (Eds). The Australian Centre for Hepatitis Virology, Melbourne, Australia (2005).
97. Van Herck K, Van Damme P, Dieussaert I, Stoffel M. Antibody persistence 10 years after immunisation with a two-dose inactivated hepatitis A vaccine, 11th International Congress on Infectious Diseases. Poster 64.012:S225, Cancun, Mexico, 4-7 March 2004.
98. Van Herck K, Beutels P, Van Damme P et al. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J. Med. Virol. 60, 1-7 (2000).
99. Bovier PA, Bock J, Loutan L et al. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J. Med. Virol. 68, 489-493 (2002).
100. Van Herck K, Renard D, Molenberghs G, Van Damme P. Model-based estimates of long-term persistence of vaccine-induced hepatitis A antibodies. 10th International Symposium on Viral Hepatitis and Liver Disease. International Medical Press, London, UK, 56-59 (2002).
101. Fan PC, Chang MH, Lee PI, Safary A, Lee CY. Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years. Vaccine 16, 232-235 (1998).
102. Fiore AE, Shapiro CN, Sabin K et al. Persistence of protective antibody levels among children vaccinated during infancy with hepatitis A vaccine differs according to maternal antibody status. Antiviral Ther. 5(Suppl. 1), 9 (2000).
103. Van Herck K, Van Damme P, Lievens M, Stoffel M. Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. J. Med. Virol. 72, 194-196 (2004).
104. Cederna JB, Klinzmann D, Stapleton JT. Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine. Vaccine 18, 892-898 (2000).
105. Desombere I, Van Herck K, Van Damme P, Thoelen S, Collard F, Leroux-Roels G. Long-term persistence of cellular immunity towards hepatitis A vaccine (HAV) following HAV vaccination. Antiviral Ther. 5(Suppl. 1), 7 (2000).
106. Purcell RH, Dhondt E, Bradbury R, Emerson SU, Govindarajan S, Binn L. Inactivated hepatitis-a vaccine - active and passive immunoprophylaxis in chimpanzees. Vaccine 10(Suppl. 1), S148-S151 (1992).
107. Robertson BH, Dhondt EH, Spelbring J, Tian HW, Krawczynski K, Margolis HS. Effect of postexposure vaccination in a chimpanzee model of hepatitis-a virus-infection. J. Med. Virol. 43(3), 249-251 (1994).
108. Shaw FE, Sudman JH, Smith SM et al. A community-wide epidemic of hepatitis A in Ohio. Am. J. Epidemiol. 123, 1057-1065 (1986).
109. McMahon BJ, Beller M, Williams J, Schloss M, Tanttila H, Bulkow L. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch. Pediatr. Adolesc. Med. 150, 733-739 (1996).
110. Prikazsky V, Olear V, Cernoch A, Safary A, André FE. Interruption of an outbreak of hepatitis A in two villages by vaccination. J. Med. Virol. 44, 457-459 (1994).
111. Syed NA, Hearing SD, Shaw IS et al. Outbreak of hepatitis A in the injecting drug user and homeless populations in Bristol: control by a targeted vaccination programme and possible parental transmission. Eur. J. Gastroenterol. Hepatol. 15, 901-906 (2003).
112. Craig AS, Sockwell DC, Schaffner W et al. Use of hepatitis A vaccine in a community-wide outbreak of hepatitis A. Clin. Infect. Dis. 27, 531-535 (1998).
113. Kaic B, Borcic B, Ljubicic M, Brkic I, Mihaljevic I. A control in a refugee camp by active immunization. Vaccine 19, 3615-3619 (2001).
114. Irwin DJ, Millership S. Control of a community hepatitis A outbreak using hepatitis A vaccine. Commun. Dis. Public Health 2(3), 184-187 (1999).
115. Bonanni P, Colombai R, Franchi G, Lo Nostro A, Comodo N, Tiscione E. Experience of hepatitis A vaccination during an outbreak in a nursery school of Tuscany, Italy. Epidemiol. Infect. 121(1), 377-380 (1998).
116. Franco E, Giambi C, Ialacci R, Coppola RC, Zanetti AR. Risk groups for hepatitis A virus infection. Vaccine 21, 2224-2233 (2003).
117. Steffen R, Kane MA, Shapiro CN, Billo N, Schoellhorn KJ, Van Damme P. Epidemiology and prevention of hepatitis A in travellers. JAMA 272, 885-889 (1994).
118. Mannucci PM, Gdovin S, Gringeri A et al. Transmission of hepatitis A to patients with hemophilia by Factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. Ann. Intern. Med. 120, 1-7 (1994).
119. Chudy M, Budek I, Keller-Stanislawski B et al. A new cluster of hepatitis A infection in haemophiliacs traced to a contaminated plasma pool. J. Med. Virol. 57, 91-99 (1999).
120. Department of Health, Welsh Office, Scottish Office Department of Health, DHSS (Northern Ireland). Hepatitis A. In: Immunisation Against Infectious Disease. Salisbury DM, Begg NT (Eds). HMSO Publications Centre, London, UK, 85-94 (1996).
121. Villano SA, Nelson KE, Vlahov D, Purcell RH, Saah AJ, Thomas DL. Hepatitis A among homosexual men and injection drug users: more evidence for vaccination. Clin. Infect. Dis. 25, 726-728 (1997).
122. Allard R, Beauchemin J, Bedard L, Dion R, Tremblay M, Carsley J. Hepatitis A vaccination during an outbreak among gay men in Montreal, Canada, 1995-1997. J. Epidemiol. Comm. Health 55, 252-256 (2001).
123. Council of the European Communities. Council Directive 93/88/EEC of 12 October 1993 amending Directive 90/679/EEC on the protection of workers from risks related to exposure to biological agents at work (seventh individual Directive within the meaning of Article 16 (1) of Directive 89/391/EEC). Official Journal L268, 71-82 (1993).
124. Keeffe EB, Iwarson S, McMahon BJ et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 27(3), 881-886 (1998).
125. Tsang SWC, Sung JJY. Inactivated hepatitis A vaccine in Chinese patients with chronic hepatitis B infection. Aliment. Pharmacol. Ther. 13, 1445-1449 (1998).
126. Nebbia G, Giacchino R, Soncini R, Ramaccioni V, Timitilli A, Zanetti AR. Hepatitis A vaccination in chronic carriers of hepatitis B virus. J. Pediatr. 134, 784-785 (1999).
127. Ferreira CT, da Sliveira TR, Vieira SM, Taniguchi A, Pereira-Lima J. Immunogenicity and safety of hepatitis A vaccine in children with chronic liver disease. J. Pediatr. Gastroenterol. Nutr. 37, 258-261 (2003).
128. Reiss G, Keeffe EB. Review article: hepatitis vaccination in patients with chronic liver disease. Aliment. Pharmacol. Ther. 19, 715-727 (2004).
129. Almasio PL, Amoroso P. HAV infection in chronic liver disease: a rationale for vaccination. Vaccine 21, 2238-2241 (2003).
130. Catalonia, Spain introduces mass hepatitis A vaccination programme. Viral Hepatitis 8, 3-4 (1999).
131. World Health Organization. Public health control of hepatitis A: Memorandum from a WHO meeting. Bull. World Health Organ. 73(1), 15-20 (1995).
132. Viral Hepatitis Prevention Board. Hepatitis A: Disease and epidemiology. Hepatitis A update. Viral Hepatitis 6, 5-14 (1997).
133. Averhoff F, Shapiro CN, Bell BP et al. Control of hepatitis A through routine vaccination of children. JAMA 286, 2968-2973 (2001).
134. Bialek SR, Thoroughman DA, Hu D et al. Hepatitis A incidence and hepatitis A vaccination among American Indians and Alaska natives, 1990-2001. Am. J. Public Health 94(6), 996-1001 (2004).
135. Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA 294(2), 194-201 (2005).
136. Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 294(2), 202-210 (2005)
137. Lopalco PL, Salleras L, Barbuti S et al. Hepatitis A and B in children and adolescents - what can we learn from Puglia (Italy) and Catalonia (Spain)? Vaccine 19, 470-474 (2001).
138. Theamboonlers A, Jantaradsamee P, Chatchatee P et al. Molecular characterization of hepatitis-A-virus infections, in the context of two outbreaks in southern Thailand. Ann. Trop. Med. Parasitol. 96(7), 727-734 (2002).
139. Sinlaparatsamee S, Nuniem J, Kankao J et al. An outbreak of hepatitis A in school children at Nakhon Si Thammarat, southern Thailand. Southeast Asian J. Trop. Med. Public Health 26(1), 104-108 (1995).
140. Poonawagul U, Warintrawat S, Snitnhan R et al. Outbreak of hepatitis A in a college traced to contaminated water reservoir in cafeteria. Southeast Asian J. Trop. Med. Public Health 26(4), 705-708 (1995).
141. Kang J-H, Lee K-Y, Kim C-H, Sim D. Changing hepatitis A epidemiology and the need for vaccination in Korea. Asian Pac. J. Allergy Immunol. 22(4), 237-242 (2004)
142. Jutavijittum P, Jiviriyawat Y, Jiviriyawat W et al. Present epidemiological pattern of antibody to hepatitis a virus among Chiang Mai children, Northern Thailand. Southeast Asian J. Trop. Med. Public Health 33(2), 268-271 (2002).
143. Poovorawan Y, Theamboonlers A, Sinlaparatsamee S et al. Increasing susceptibility to HAV among members of the young generation in Thailand. Asian Pac. J. Allergy Immunol. 18(4), 249-253 (2000).
144. Victor J, Knudsen JD, Nielsen LP et al. Hepatitis A vaccine. A new convenient single-dose schedule with booster when long-term immunization is warranted. Vaccine 12(14), 1327-1329 (1994).